|Bid||8.83 x 1000|
|Ask||8.89 x 800|
|Day's Range||8.30 - 8.94|
|52 Week Range||2.40 - 12.73|
|Beta (5Y Monthly)||1.90|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.83|
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that CEO Nadav Kidron will be featured in a live webinar titled Grand Rounds: a Webinar in Biotech and Specialty Pharma hosted by James Molloy, Managing Director of Equity Research, Biotechnology and Specialty Pharmaceuticals at Alliance Global Partners on Monday, April 26, 2021 at 11:00 Eastern.
Oramed Pharmaceuticals Inc. ( NASDAQ:ORMP ) shareholders might be concerned after seeing the share price drop 14% in...
By M. Marin NASDAQ:ORMP | NASDAQ:VXRT | NASDAQ:ALT READ THE FULL ORMP RESEARCH REPORT Advantages include ease of storage & distribution, plus potential to overcome vaccine hesitancy Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has announced the formation of a new joint venture with India-based Premas Biotech, Oravax Medical Inc., to advance an orally administered vaccine for the COVID-19 virus.